|
|
home > white papers > Clinical Trials in Russia Orange Paper: 1st Quarter 2014 - Synergy Research Group |
 |
 |
WHITE PAPERS |
|
Synergy Research Group
|
Clinical Trials in Russia Orange Paper: 1st Quarter 2014
|
In summary, Russia remains a very popular geography for local, regional,
and global pharmaceutical companies to conduct clinical trials.
Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4.
Low cost: Average per patient cost is 60% to 70% below US and European
prices due to the low cost of Investigators and the high concentration
of patients in therapeutically aligned medical centers
|
|
|
|
|
 |
 |
News and Press Releases |
 |
ynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Approvals based on the PAOLA-1, PROfound and POLO Phase III trials
More info >> |
|
 |
White Papers |
 |
Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?
Eurofins BioPharma Product Testing
As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
|